Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, announced its participation in the upcoming 27th Annual H.C. Wainwright Global Investment Conference from September 8-10th, 2025.

CEO Richard Christopher will deliver a company presentation, which will be available for remote viewing starting September 5th at 7:00 AM EST. The management team will also be available for one-on-one meetings with investors throughout the conference.

KELOWNA, BC / ACCESS Newswire / August 27, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it will participate in the 27^th Annual H.C. Wainwright Global Investment Conference, taking place September 8^th through September 10^th, 2025.

Richard Christopher, Chief Executive Officer of Lexaria Bioscience, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. His presentation will be available for remote viewing anytime after 7:00 AM EST on September 5^th at this provided link.

Event Details:

• Conference: 27^th Annual H.C. Wainwright Global Investment Conference

• Date: September 8-10^th, 2025

Investors interested in scheduling a meeting with the Lexaria management team should contact their H.C. Wainwright representative or send an email to: meetings@hcwco.com

About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

View the original press release on ACCESS Newswire

FAQ

When is Lexaria Bioscience (LEXX) presenting at the H.C. Wainwright Conference 2025?

Lexaria's presentation will be available for remote viewing starting September 5th, 2025 at 7:00 AM EST, with the conference running from September 8-10th, 2025.

How can investors schedule meetings with Lexaria (LEXX) management at the H.C. Wainwright Conference?

Investors can schedule meetings by contacting their H.C. Wainwright representative or by sending an email to meetings@hcwco.com.

Who will be presenting for Lexaria Bioscience at the H.C. Wainwright Conference?

Richard Christopher, Chief Executive Officer of Lexaria Bioscience, will deliver the company presentation.

What does Lexaria Bioscience (LEXX) do?

Lexaria Bioscience is a global innovator in drug delivery platforms.